Table 3.

Best Response Rates During Dasatinib Treatment for Patients Who Discontinued Dasatinib to Undergo Allogeneic Stem Cell Transplantation

Dasatinib Regimen	Best CyRa	Duration of MCyR, db	Best Hematologic Responsec	Duration of MHR, db
CML in myeloid blast phase
Dasatinib 140 mg QD
Patient 1	Complete	1	Complete	62
Patient 2	Minimal	NA	NEL	292
Patient 3	Partial	1	No response	NA
Dasatinib 70 mg BID
Patient 4	Complete	1	NEL	56
Patient 5	Partial	1	No response	NA
Patient 6	No response	NA	No response	NA
Patient 7	Complete	1	No response	NA
Patient 8	Partial	1	No response	NA
Patient 9	No response	NA	No response	NA
CML in lymphoid blast phase
Dasatinib 140 mg QD
Patient 10	Complete	96	No response	NA
Patient 11	Complete	118	NEL	144
Patient 12	Complete	138	Complete	208
Patient 13	Minimal	NA	No response	NA
Patient 14	Unable to determine	NA	No response	NA
Dasatinib 70 mg BID
Patient 15	Complete	57	No response	NA

CyR indicates cytogenetic response; MCyR, major cytogenetic response; MHR, major hematologic response; CML, chronic myeloid leukemia; QD, once daily; NA, not applicable; NEL, no evidence of leukemia; BID, twice daily.

^aAn MCyR was defined to include either a complete or partial cytogenetic response.

^bCensored at the last hematologic or cytogenetic assessment.

^cAn MHR was defined to include either a complete hematologic response or NEL.